Red
Brand Name(s):
Indication:Delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies
Rationale:1,2,8
Considered:Nov-20
Review Date:Nov-25
Comments:
Rituximab is recommended to be available as a treatment option through routine commissioning for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies.